Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Du musst dich anmelden oder registrieren, bevor du fortfahren kannst.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

DGAP-News: Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency
DGAP-News: Biotest AG: Biotest achieves important milestone in Phase III study in acquired fibrinogen deficiency
eqs_en 
0 10.06.22
DGAP-News: Biotest AG: Biotest AG opens 11th plasma collection centre in Czech Republic: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest AG opens 11th plasma collection centre in Czech Republic
DGAP-News: Biotest AG: Biotest AG opens 11th plasma collection centre in Czech Republic
eqs_en 
0 09.06.22
DGAP-News: Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology: https://mms.businesswire.com/media/20200216005057/en/682845/5/logo_color_high_res.jpg
DGAP-News: Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology
DGAP-News: Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology
eqs_en 
0 07.06.22
DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
eqs_en 
0 30.05.22
DGAP-News: ​​​​​​​PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS MICHAEL SCHLENK AND GREGOR SIEBERT TO THE SUPERVISORY BOARD: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
DGAP-News: ​​​​​​​PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS MICHAEL SCHLENK AND GREGOR SIEBERT TO THE SUPERVISORY BOARD
DGAP-News: ​​​​​​​PAION AG: ANNUAL GENERAL MEETING APPROVES ALL AGENDA ITEMS AND ELECTS MICHAEL SCHLENK AND GREGOR SIEBERT TO THE SUPERVISORY BOARD
eqs_en 
0 25.05.22
DGAP-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Czech Republic: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Czech Republic
DGAP-News: Biotest AG: Biotest AG opens 10th plasma collection centre in Czech Republic
eqs_en 
0 24.05.22
DGAP-News: HAEMATO AG publishes figures for Q1 2022: further improvement in EBIT margin and confirmation of guidancehttp://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png
DGAP-News: HAEMATO AG publishes figures for Q1 2022: further improvement in EBIT margin and confirmation of guidance
DGAP-News: HAEMATO AG publishes figures for Q1 2022: further improvement in EBIT margin and confirmation of guidance
eqs_en 
0 23.05.22
DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology
DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology
eqs_en 
0 19.05.22
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
eqs_en 
0 18.05.22
DGAP-News: ​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2022: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
DGAP-News: ​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2022
DGAP-News: ​​​​​​​PAION AG PUBLISHES GROUP QUARTERLY STATEMENT FOR THE FIRST QUARTER OF 2022
eqs_en 
0 18.05.22
DGAP-News: Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes
DGAP-News: Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes
eqs_en 
0 17.05.22
DGAP-News: MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
DGAP-News: MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
eqs_en 
0 12.05.22
DGAP-News: Evotec SE reports results for the first quarter 2022 and provides corporate update: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE reports results for the first quarter 2022 and provides corporate update
DGAP-News: Evotec SE reports results for the first quarter 2022 and provides corporate update
eqs_en 
0 11.05.22
DGAP-News: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
DGAP-News: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
eqs_en 
0 10.05.22
DGAP-News: Biotest AG: Dr Bernhard Ehmer new Chairman of the Supervisory Board of Biotest AG: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Dr Bernhard Ehmer new Chairman of the Supervisory Board of Biotest AG
DGAP-News: Biotest AG: Dr Bernhard Ehmer new Chairman of the Supervisory Board of Biotest AG
eqs_en 
0 06.05.22
DGAP-News: Biotest AG: Annual General Meeting approves dividend distribution: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Annual General Meeting approves dividend distribution
DGAP-News: Biotest AG: Annual General Meeting approves dividend distribution
eqs_en 
0 05.05.22
DGAP-News: Biotest AG: Biotest records sales of € 115 million in the first quarter of 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest records sales of € 115 million in the first quarter of 2022
DGAP-News: Biotest AG: Biotest records sales of € 115 million in the first quarter of 2022
eqs_en 
0 05.05.22
DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results
DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results
eqs_en 
0 04.05.22
DGAP-News: Evotec SE to announce results for the first quarter 2022 on 11 May 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23749/Evotec_high_res_logo_%28blue_and_grey%29.jpg
DGAP-News: Evotec SE to announce results for the first quarter 2022 on 11 May 2022
DGAP-News: Evotec SE to announce results for the first quarter 2022 on 11 May 2022
eqs_en 
0 04.05.22
DGAP-Adhoc: HAEMATO AG: Dividend of EUR 1.10http://www.haemato-ag.de/: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/13910/haematoLogo.png
DGAP-Adhoc: HAEMATO AG: Dividend of EUR 1.10
DGAP-Adhoc: HAEMATO AG: Dividend of EUR 1.10
eqs_en 
0 03.05.22
DGAP-News: Biotest AG: Biotest Supervisory Board appoints new Management Board member: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Biotest Supervisory Board appoints new Management Board member
DGAP-News: Biotest AG: Biotest Supervisory Board appoints new Management Board member
eqs_en 
0 02.05.22
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24061/Morphosys-logo.svg.png
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
eqs_en 
0 28.04.22
DGAP-Adhoc: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA: https://upload.wikimedia.org/wikipedia/de/thumb/4/45/Paion-logo.svg/640px-Paion-logo.svg.png
DGAP-Adhoc: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA
DGAP-Adhoc: PAION GRANTS EXCLUSIVE LICENSE TO CRISTÁLIA FOR DEVELOPMENT AND COMMERCIALIZATION OF REMIMAZOLAM IN LATIN AMERICA
eqs_en 
0 27.04.22
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
DGAP-Adhoc: QIAGEN N.V.: QIAGEN increases full-year 2022 outlook
eqs_en 
0 26.04.22
DGAP-News: Biotest AG: Grifols acquires majority of voting rights in Biotest: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24092/375px-Biotest_logo.svg.png
DGAP-News: Biotest AG: Grifols acquires majority of voting rights in Biotest
DGAP-News: Biotest AG: Grifols acquires majority of voting rights in Biotest
eqs_en 
0 25.04.22